Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1996-2-8
|
pubmed:keyword | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
E
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0007-1331
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
76 Suppl 2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
37-40
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8535752-Antineoplastic Agents,
pubmed-meshheading:8535752-Clinical Trials as Topic,
pubmed-meshheading:8535752-Disclosure,
pubmed-meshheading:8535752-Ethics, Medical,
pubmed-meshheading:8535752-Neoplasms,
pubmed-meshheading:8535752-Risk Assessment,
pubmed-meshheading:8535752-Truth Disclosure
|
pubmed:year |
1995
|
pubmed:articleTitle |
Ethical issues in cancer treatment.
|
pubmed:affiliation |
Medical Oncology Department, St Bartholomew's Hospital, London, UK.
|
pubmed:publicationType |
Journal Article,
Review
|